Medivir AB (publ) (MVIR-B.ST) Research

Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.

Market snapshot

Symbol
MVIR-B.ST
Price
$7.22
Day change
+1.12%
Market cap
$402.3M
P/E ratio
-4.51x
52-week range
6.92-10.52
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Abliva AB (publ) (ABLI.ST)
  • Amniotics AB (publ) (AMNI.ST)
  • CombiGene AB (publ) (COMBI.ST)
  • Idogen AB (publ) (IDOGEN.ST)
  • ISR Immune System Regulation Holding AB (publ) (ISR.ST)
  • Kancera AB (publ) (KAN.ST)
  • Lipidor AB (publ) (LIPI.ST)
  • Pharmiva AB (publ) (PHARM.ST)

Open Medivir AB (publ) (MVIR-B.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.